Share Twitter LinkedIn Facebook Email Pascal Besman, Chief Operating Officer of PharmaMar, shares Investigator Sponsored Trials in Europe & US | With Immuno-Oncology Checkpoint Inhibitors at Annual Meeting 2018
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read